SemaThera Inc Information

SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). The technology targets the 30% DME patients who are poor responders to current anti-VEGF therapies.

Website	http://www.semathera.com
Revenue	$811000
Employees	4 (2 on RocketReach)
Founded	2016
Address	227 Ave Westminster N, Montreal, Quebec H4X 1Z5, CA
Phone	+1 617-395-8580
Technologies	JavaScript , HTML , PHP +10 more (view full list)
Industry	Biotechnology, Biotechnology Research, Manufacturing General, Diabetic Macular Edema, Manufacturing, Science and Engineering, Other Healthcare Services, Ocular Diseases, Diabetes, Semaphorin 3A, Health Care, Therapeutics
Keywords	Bispecific Antibodies, Inflammation Treatment, Therapeutic Antibodies, Targeted Therapy, Cancer Therapeutics, Drug Development, Pharmaceutical Research, Protein Therapeutics, Immunotherapy, Oncology, Precision Medicine, Biologics, Biotechnology, Clinical Trials
Competitors	Roche, Novartis, AbbVie, Merck & Co., Inc., Pfizer, AstraZeneca, Bristol Myers Squibb, Amgen, Gilead Sciences, Lilly India +43 more (view full list)
SIC	SIC Code 28 Companies, SIC Code 283 Companies
NAICS	NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies